Don't Argue With the Market<br />By Rev Shark<br />RealMoney.com Contributor<br />7/30/2009 8:33 AM EDT <br /><br />The next mile is the only one a person really has to make. <br />-- Danish fur trapper's expression <br />One of the easiest ways to find yourself out of step with the market is to look too far down the road. We can always make a good argument for why things are bound to eventually change, but it seldom pays to argue with what is presently happening in front of us. <br /><br />The market has a tendency to trend, and those trends don't end easily or logically. Most often, they will persist far longer than we think are reasonable and they will reverse only when few are prepared for it. <br /><br />The present rally, which kicked off a couple weeks ago on earnings from Goldman Sachs (GS) and Intel (INTC) is a particularly good example of a trend. It has already gone much further than most would have predicted and has been astonishing in its persistence and lack of pullbacks. <br /><br />For many, including me, the breathless excitement in the market seems out of step with the much more sober views on Main Street. While Wall Street is celebrating the deceleration or our economic meltdown, many ordinary folks are still very concerned about unemployment, real estate prices and the pace of any recovery. <br /><br />Bur our job as traders isn't to worry too much about how realistic the market might be but rather to embrace what is happening now and try to profit form it. What is happening now is a tremendously strong rally that has many folks scrambling to find a way to enter this market. They aren't seeing any meaningful pullbacks, so they are paying up and chasing stocks that, in many cases, are already extended. <br /><br />How much further will this extended market run before we have a meaningful correction? I have no idea, and I'm not going to try to anticipate it. I'll simply accept the fact that we have a strong market and try not to question it. <br /><br />One of the easiest ways to improve your investment results is to simply not argue with the market. It is not a rational beast, and no matter how logical or insightful you might be, you are never going to win an argument with the market. It may eventually come around to your viewpoint, but you can become broke pretty fast if your timing is off. <br /><br />This morning the market is seeing strength once again as Asian markets recovered from a one-day thumping and a flow of good earnings reports continued. It isn't easy to find new buys in this market, but it is far more dangerous to not respect this great strength. <br />----------------------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: ITP +17.6%, SONS +17.4%, NAVR +15.5%, TRMA +15.1%, BIOS +13.6%, PTI +13.2% (light volume), BT +11.6%, AMSC +11.4%, NWL +8.6%, MOT +8.1%, AMKR +7.1%, MA +7.1%, CVC +7.0%, DAVE +6.7%, ALU +6.7%, CPF +6.6%, CI +6.3%, SNE +6.0%, BSY +5.8%, LSI +5.7% (upgraded to Buy form Neutral at Goldman - Reuters), SMMX +5.3% (light volume), HIG +5.3%, FLS +5.3%, WYNN +4.8%, IP +3.3%, MYL +3.0%, ESRX +2.8%, AZN +2.6%, AHL +2.4%, AGNC +2.3%, AEM +1.5% (also Cramer makes positive comments on MadMoney), TYC +1.0%... M&A news: OSP +12.7% (Overseas Shipholding proposes to acquire remaining public stake for $8.00/unit in cash)... Select metals/mining names showing strength: RTP +5.8%, AAUK +4.0%, BHP +3.9%, MT +3.7%... Select oil/gas related names trading higher: STO +2.1%, SLB +1.9%, RIG +1.8%, PBR +1.7%, OXY +1.3%... Select financials showing strength: IRE +7.0%, AIB +5.3%, IBN +5.2%, MET +3.6%, PRU +3.0%, HBC +2.9%, FITB +2.8%, BAC +1.6%, UBS +1.4%, ABB +1.2%... Select drug related names trading higher: PFE +1.5% (Pfizer and Medivation initiate phase 3 trial of dimebon in patients with Huntington Disease), GSK +1.0%... Other news: VRNM +55.4% (Verenium and BP announce partnership to advance the commercialization of cellulosic ethanol), AXL +15.0% (continued strength), ARIA +10.6% (still checking), AIS +10.5% (receives payment from Teva for commercial development of Vibex Auto-Injector product), WXCO +9.1% (still checking), LVS +3.9% (up in sympathy with WYNN), POT +2.0% (Cramer makes positive comments on MadMoney)... Analyst comments: RCL +4.8% (upgraded to Equal Weight at Barclays), GE +4.6% (upgraded to Buy from Neutral at Goldman- DJ), RF +2.8% (upgraded to Neutral at BofA/Merrill), BDN +2.5% (upgraded to Buy at Argus), YUM +2.2% (upgraded to OVerweight at Morgan Stanley), SAP +1.9% (upgraded to Hold at SocGen), AMZN +1.3% (initiated with a Buy at UBS). <br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: LVLT -13.6%, AKAM -11.3% (also multiple analyst downgrades), FBP -10.1% (light volume), GMR -9.3%, SYMC -8.4%, OCR -7.3%, CTV -6.0%, DRIV -5.4%, GMCR -5.2%, FLEX -4.5% (downgraded to Hold at Needham), FISV -3.8%, CERN -3.8%, ASIA -2.9%, WMI -2.8%, VAR -2.8%, PH -2.7%, XOM -2.1%, (CML -1.5% (light volume), CL -2.0%... Other news: RUK -14.2% (Reed Elsevier shares plunge in Europe on share placement - DJ), ENL -14.2% (still checking), INO -12.9% (announces $30 mln registered direct offering), ENL -11.0% (still checking), TOO -8.9% (announces it has priced its public offering of 6.5 mln shares of common stock at $14.32/share), MITI -8.8% (announced that it intends to offer shares of its common stock in a public offering), CSFL -8.2% (light volume, prices 11.54 mln common shares at $6.50/share), RCRC -5.6% (announced that it priced a public offering of 3,500,000 shares of common stock; expects to receive net proceeds from the offering of approximately $49.6 mln), GHL -5.1% (announces 3,000,000 share common stock offering), HRBN -2.2% (prices a public offering of 6,250,000 shares at $16.00 per share)... Analyst comments: CATY -6.5% (downgraded to Neutral at B. Riley), CML -6.3% (downgraded to Accumulate at ThinkEquity), THOR -4.1% (downgraded to Hold from Buy at Lazard Capital Mkts).